Mankind Pharma Ltd

Stage 3 · Topping · week 4

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. More about the company

₹2,500
+0.00% today
₹1.03L Cr · Large cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-4.5%
₹1,927.4 lo₹2,617.9 hi
Near 52W high — distribution zone
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 4
1w13w26w
Week 4 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
8.7%
200 DMA: ₹2,299.6 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.51x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↗ ⇈
Accelerating · MA20 +2.6% vs MA50 -2.0% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+7.4%
3M
+0.4%
6M
+23.9%
YTD
+12.1%
1Y
+1.5%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
Sector has 77 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Industry has 61 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-12 → 2026-10-07
S? 32w
S2 15w
S2 23w
S4 23w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 32w → S2 15w → S3 10w → S2 23w → S3 6w → S4 8w → S1 7w → S4 4w → S1 5w → S2 5w → S3 6w → S4 23w → S1 6w → S2 13w → S3 4w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-11
4 appearances in last 60 days. First seen: 2024-02-26.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S3
Wk 4 · Vol 0.51x
2026-10-06S3
Wk 4 · Vol 0.63x
2026-10-05S3
Wk 4 · Vol 1.14x
2026-10-01S3
Wk 4 · Vol 0.93x
2026-09-30S3
Wk 3 · Vol 3.00x
2026-09-29S3
Wk 3 · Vol 4.81x
2026-09-28S3
Wk 3 · Vol 0.95x
2026-09-25S3
Wk 3 · Vol 0.81x
2026-09-24S3
Wk 3 · Vol 1.05x
2026-09-23S3
Wk 2 · Vol 0.83x
2026-09-22S3
Wk 2 · Vol 1.60x
2026-09-21S3
Wk 2 · Vol 3.34x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹2,414.5
200 DMA
₹2,299.6
52W High
₹2,617.9
52W Low
₹1,927.4
5D Low
₹2,479
Resistance levels (recent highs)
20d High
₹2,545
60d High
₹2,617.9
120d High
₹2,617.9
250d High
₹2,617.9
Next resistance
+1.8%
to 20d High
Ask the Market AI about MANKINDAsk →
P/E (TTM)
52.3
Forward 33.7
Earnings Growth (YoY)
+31.7%
Revenue +11.8%
ROE
+12.5%
Profit margin +13.4%
Dividend Yield
0.08%
P/B 6.5
About this companyHealth Care· Pharmaceuticals

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.